Novel Targets Of Neoantigens In Monoclonal Antibodies

Philip M. Arlen, M.D.

Summary: 

• Target is broadly expressed in multiple solid tumors.
• Exhibits both ADCC and CDC killing.
• Promising pre-clinical results with complete regression of tumor in animal models.
• GMP manufacturing completed.
• Pre-clinical testing showed that NEO-201 was well tolerated in cynomolgus monkeys even at high doses.
• Preclinical changes in hematologic laboratory values represents an on-target side effect that
  appears to be reversible, and supports infusion schedule of every two weeks.
• FDA approved IND July 2018
• 1st in Human Study initiated at NCI Q1 2019

Novel Targets of Neoantigens in Monoclonal Antibodies